Content Type: Article

  • Proposed Bill Would Create New Tax Regime Introducing Uncertainty and Threatening Broad Credit Markets and Beyond

    Proposed Bill Would Create New Tax Regime Introducing Uncertainty and Threatening Broad Credit Markets and Beyond

    ARTICLE / CLIENT ALERT

    Proposed Bill Would Create New Tax Regime Introducing Uncertainty and Threatening Broad Credit Markets and Beyond

    June 18, 2025

    Read time: 8 min

    Key takeaways
    Overview

    On May 20, 2025, Senator Thom Tillis (R-NC) introduced the Tackling Predatory Litigation Funding Act as an amendment to the Internal Revenue Code of 1986 (the “Code”), which would establish a new tax regime purportedly applicable to third-party litigation funding. A companion bill was introduced in the House of Representatives (the “House”) on the same day by Representative Kevin Hern (R-OK). On May 21, 2025, the House passed the One Big Beautiful Bill Act, which would make significant changes to the Code but which did not contain the Tillis proposal. On June 16, 2025, the Senate Finance Committee released a draft Reconciliation Bill (the “Bill”), which included the Tillis proposal without substantial change. While the Bill purports to address litigation funding, if enacted, the Bill would have an impact on broader financial markets, injecting uncertainty into numerous ordinary course financing transactions and potentially chilling corporate credit and other credit markets. In addition, the legislation would set a troubling precedent for addressing perceived grievances relating to different sectors of the economy.

    While the stated goal is to prevent foreign influence in the US court system and prevent frivolous lawsuits, the Bill goes far beyond simply imposing a special rate on qualified litigation proceeds and essentially creates an entirely new income tax system dedicated to the litigation finance industry. The Bill would depart from the traditional Code’s longstanding flow-through approach to non-corporate entities, would completely disregard the tax characterization of the instrument under which qualified litigation proceeds are received and would seek to tax foreigners and tax-exempts (including US pension plans and other tax-exempt entities) in a manner that is inconsistent with the traditional US income tax system. There is little precedent for the establishment of an entirely new income tax system dedicated to a particular industry. Furthermore, under the wording of the legislative text, even ordinary course financing transactions (including secured and unsecured lending, securitizations and debtor-in-possession lending) could be picked up, potentially impacting broader financial markets.

    Overview of the Proposed Tax

    The Bill would add a new Chapter 50B to the Internal Revenue Code, imposing a tax on “qualified litigation proceeds” received by “covered parties” under a “litigation financing agreement.” Key provisions include:

    • Flat tax rate of 40.8% (equal to the current top individual tax rate of 37% plus 3.8%), on all qualified litigation proceeds. Qualified litigation proceeds include the realized gains, net income or other profit which is derived from, or pursuant to, any litigation financing agreement.
    • Imposition of an entity-level tax, including for partnerships and S corporations, overriding traditional flow-through principles.
    • Broad scope of “covered parties,” includes individuals, corporations, partnerships, sovereign wealth funds and tax-exempt organizations (including US pension plans and other tax-exempt entities), regardless of US or foreign status.
    • Expansive definition of “litigation financing agreement,” includes not only traditional litigation funding contracts but also any agreement “which creates a direct or collateralized interest” in litigation outcomes. In addition, the Treasury would have authority to treat substantially similar arrangements, which are undefined, as subject to the tax. Therefore, any general asset financing provided to an entity that is a named plaintiff in a civil litigation could potentially be considered within the scope of the legislation, and it is unclear what other arrangements Treasury and/or the IRS might consider to be in scope.
    • No offset for losses: Unlike typical taxable income, qualified litigation proceeds cannot be offset by other ordinary or capital losses, even those generated by other litigation financing arrangements.
    • Overrides key traditional exclusions, exemptions and preferences, including:
      • Section 104(a)(2): Exclusion for personal physical injury damages;
      • Section 892: Exemption for income earned by foreign governments;
      • Sections 871(h) and 881(c): Portfolio interest exemption; and
      • No preferential capital gain treatment.
    • New withholding regime: Any named party in a civil action or law firm affiliated with such civil action that has entered into a litigation financing agreement with respect to such civil action and has control, receipt or custody of proceeds with respect to such civil action must withhold 50% of the applicable tax rate (currently 20.4%) from all payments made to the funder. The withholding obligation is not based on net income or profit.
    • Narrow exclusions for (i) fundings below $10,000, (ii) debt-like arrangements with interest rates capped at the greater of 7% or two times the average annual yield on 30-year Treasury securities and (iii) certain related-party transactions.

    The bill would apply to taxable years beginning after Dec. 31, 2025 and would presumably apply even to existing litigation funding arrangements entered into prior to Dec. 31, 2025.

    Impact of the Bill

    If enacted, the Bill would create a completely new income tax regime, which purports to only apply to litigation financing transactions but would potentially have a much broader reach, likely resulting in significant uncertainty regarding its interaction with the traditional tax system and posing complex compliance challenges, including:

    • Ambiguity for certain common commercial transactions: The definition of a “litigation financing agreement” could sweep in ordinary corporate credit transactions where the debtor is a party to a civil litigation, including whole business and other securitizations, purchases of subrogation claims from Insurance Companies, factoring deals and other unintended arrangements.
    • Double taxation risk for investments through entities:
    • Corporations:
    • Ordinarily, earnings and profits of a US corporation that are distributed to individual shareholders are generally subject to a second level of tax at a maximum rate of 20% or 37%, depending on whether or not the distributions are “qualified dividends.” In addition, dividends from a corporation are generally subject to a net investment income tax of 3.8%. 
    • Therefore, in the case of a litigation funding investment made through a US corporation, if the proceeds of the litigation funding are subject to a second level of tax when they are distributed from the corporation in the same manner as other distributed corporate earnings, the highest marginal effective federal rate applicable to individuals invested in the litigation financing through a corporation (including the tax imposed on the corporation itself) would be either 54.89% if the distributions are qualified dividends, or 64.95% if they are not.
    • While the legislation would carve out qualified litigation proceeds from gross income, it is unclear whether this would also carve out qualified litigation proceeds from earnings and profits. Even if qualified litigation proceeds are not included in earnings and profits, it is likely that distributions of qualified litigation proceeds would reduce the shareholders’ adjusted basis in their corporate shares.
    • Partnerships:
        • Furthermore, there could be double tax on income from litigation funding even when the litigation funding investment is made through a partnership. In contrast with the traditional flow-through treatment of partnerships, the Bill would impose the tax on partnerships themselves. Since the legislation would carve out qualified litigation proceeds from gross income of the partnership, presumably, partners’ basis in their partnership interests would not be increased by the qualified litigation proceeds.
        • Consequently, proceeds from an investment in a litigation financing arrangement through a partnership would effectively be subject to double tax, once, upon receipt of the proceeds by the partnership, and again, upon distribution to the partners. Gains recognized under Section 731 on distributions from a partnership are generally subject to net investment income tax.
        • Accordingly, the highest marginal effective federal rate on qualified litigation proceeds earned through a partnership would be 54.89% if the partners held their interests in the partnership for more than a year, or 64.95% if they did not.
    • Tax-exempt investors, foreign governments and portfolio interest: The Bill would override a number of long-standing, traditional tax exemptions. The legislation would impose a tax on tax-exempt investors (including US pension plans and other tax-exempt entities) and on foreign governments that are both generally exempt from tax on various categories of passive income. In addition, the tax would override the portfolio interest exemption that generally exempts US source interest paid to foreign lenders from US withholding tax.
    • Foreign investor exposure: The tax would apply to non-US investors even if the litigation financing income would be considered capital gain under general income tax principles, which would not ordinarily be subject to US tax.
    • Foreign litigation: The legislation does not distinguish between US and foreign litigation. Therefore, both US and non-US investors that are covered persons would technically be subject to the tax even if the litigation funding relates to non-US litigation.

    Takeaways

    The Bill would establish a standalone income tax regime that departs from the traditional US income tax framework in both scope and structure and would override a number of long-standing income tax principles such as the treatment of partnerships and forward contracts, favorable tax treatment for tax-exempt entities and foreign governments, and the portfolio interest exemption. Although the legislation purports to only target litigation funding, if enacted the Bill would have an impact on broader credit markets (including secured and unsecured lending, securitizations and debtor-in-possession lending) and would set a troubling precedent for addressing other disfavored financial activities through inadequately considered tax legislation.

    Authored by Andi Mandell, Chaim Stern, Boris Ziser and Sarah J. McNeill.

    We are continuing to monitor any developments with the Bill as it makes its way through Congress. If you have questions concerning this Alert, please contact your attorney at Schulte.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Boris Ziser

    Partner

    New York – 919 Third Avenue

    Sarah J. McNeill

    Associate

    New York – 919 Third Avenue

    More insights

  • Recent New York Legislation Restricts Institutional Investors’ Purchases of Residential Real Estate

    Recent New York Legislation Restricts Institutional Investors’ Purchases of Residential Real Estate

    ARTICLE / CLIENT ALERT

    Recent New York Legislation Restricts Institutional Investors’ Purchases of Residential Real Estate

    June 16, 2025

    Read time: 9 min

    Key takeaways
    Overview

    Commencing on July 1, 2025, investment funds may find it more difficult to purchase certain residential properties in New York State. On May 9, 2025, Governor Hochul signed into law Assembly Bill A3009C that, among other things, (i) imposes a 90-day waiting period on the purchase of one- and two-family residences for certain institutional investors, (ii) restricts the use of certain tax deductions for such investors, and (iii) requires the Secretary of State to provide public notice when creating cease and desist zones.[1]

    A3009C’s restrictions are directed at the purchase of Single- and Two-Family Residences.[2]Subject to limited exceptions, these restrictions generally apply to entities or combined groups that directly or indirectly (i) own ten or more Single- or Two-Family Residences, (ii) manage or receive funds pooled from investors and act as fiduciaries with respect to those investors, and (iii) have at least $30 million in net value or assets under management on any day during a given taxable year (“Covered Entities”).[3]

    Under the 90-day waiting period, Covered Entities may not “purchase, acquire, or offer to purchase or acquire” any interest in a Single- or Two-Family Residence unless that property has been “listed for sale to the general public” for 90 days.[4]Further, when a Covered Entity offers to purchase a Single- or Two-Family Residence, it must provide notice of its status as a Covered Entity to the seller or the seller’s agent.[5]Failing to comply with these requirements can result in civil damages and penalties of up to $250,000 for violations of the waiting period and up to $10,000 for violations of the notice requirement.

    A3009C also prohibits Covered Entities, as well as their partners, members, and shareholders, from claiming depreciation or interest tax deductions with respect to Single- and Two-Family Residences when calculating their income for state tax purposes.[6]Further, the law requires the New York Department of State to provide public notice on its website when it creates “cease and desist zones.” Homeowners that opt into the coverage of a zone cannot be solicited to sell their homes. The 90-day waiting period and cease and desist zone rule take effect July 1, 2025, while the prohibition on deductions takes effect immediately.

    Institutional investors should note that these restrictions are not the only limitations on their ability to acquire residential property that have been proposed to the New York legislature. Senate Bill S1572, the “End Hedge Fund Control of New York Homes Act,” would require certain pooled investment vehicles to divest of all currently owned residential properties that consist of one to four dwelling units over ten years, with limited exceptions.[7]S1572 would also impose an excise tax on pooled investment vehicles’ future purchases of certain residences consisting of one to four dwelling units equal to 50 percent of the fair market value of the residence.

    While S1572 remained in the Senate Committee on Investigations and Government Operations without any action during the 2025 legislative session, the bill may move forward during the 2026 legislative session. If S1572 does not pass during the 2025-2026 legislative term, it could be reintroduced in 2027.[8]

    New York is not the only state considering restricting the ability of investment funds to purchase residential property. There are bills being considered by at least six other states, as well as the US Senate, that would enact various limitations, ranging from constraining the maximum number of properties that may be owned to requiring the divestiture of residences.[9]

    Since these efforts are unlikely to diminish in the near-term, institutional investors should remain cognizant of the evolving legal landscape and take these proposed restrictions into account when making investment decisions.

    Authored by Julia Beskin, Julian M. Wise, and Mathew R. Swan.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] A.B. A3009C, N.Y. Assemb. (N.Y. 2025).

    [2] A3009C does not apply to a residence that (i) is “constructed, acquired, or operated with federal, state, or local appropriated funding sources” or (ii) is intended to be used as the “principal residence of any person who has an ownership interest in the covered entity that seeks to purchase the single-family residence.”

    [3] The 90-day waiting period also applies to entities that receive funding from Covered Entities to purchase a Single- or Two-Family Residence.

    [4] If a seller changes the asking price for the property, the 90-day waiting period restarts.

    [5] Such notice must be filed with the Department of Law within three days of submitting it to the seller or the seller’s agent.

    [6] A3009C does not affect Covered Entities’ ability to claim these deductions for federal tax purposes.

    [7] S.B. S1572, N.Y. S. (2025).

    [8] A version of this bill was previously introduced during the 2023-2024 legislative term as Senate Bill S9096.

    [9] S. 788, 119th Cong. (2025); S.B. 722, Cal. S. (Cal. 2025); H.B. 305, Ga. Gen. Assemb. (Ga. 2025); H.B. 237, Ky. Gen. Assemb. (Ky. 2025); H,B, 149, Utah H. of Reps. (Utah 2025); S.B. 1140, Va. S. (Va. 2025); S.B. 1424, Va. S. (Va. 2025); S.B. 5496, Wash. S. (Wash. 2025).


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Julia Beskin

    Partner

    New York – 919 Third Avenue

    Julian M. Wise

    Partner

    New York – 919 Third Avenue

    Mathew R. Swan

    Associate

    New York – 919 Third Avenue

    More insights

  • Connecticut can’t help itself, amends consumer privacy law again

    Connecticut can’t help itself, amends consumer privacy law again

    ARTICLE / CLIENT ALERT

    Connecticut can’t help itself, amends consumer privacy law again

    June 13, 2025

    Read time: 6 min

    Key takeaways
    Overview

    On June 3, 2025, the Connecticut legislature passed a bill amending the Connecticut Data Privacy Act (CTDPA). The amendment introduces a variety of changes, including a broadening of the CTDPA’s applicability, changed exemptions, new definitions and consumer rights, and additional required disclosures in privacy policies. If signed by the governor, the amendments will go into effect on July 1, 2026.

    In depth

    Broadened Applicability

    The CTDPA now applies to entities doing business in Connecticut that 1) process 35,000 consumers’ data; 2) control or process consumers’ sensitive data; or 3) offer consumers’ personal data for sale. This is greatly broadened, as the CTDPA formerly only applied to entities that processed over 100,000 consumers’ data or derived 25% or more of their gross revenue from the sale of data and processed over 25,000 consumers’ data. Data processed solely for payment transactions is excluded from these thresholds.

    Exemptions

    The amended CTDPA narrows the Gramm-Leach-Bliley Act exemption to a data-level exemption from the original laws’ entity-level exemption. However, the amendments introduce an exemption for bona fide financial institutions like insurers, investment advisors, banks, and credit unions. The amended CTDPA also no longer applies to political committees.

    New Rights

    The amended CTDPA allows consumers to request a variety of new information, including if any inferences are being made using their data or if any profiling is occurring using their data. If the profiling is used to significant effect, the consumer may be able to request to review the data used, correct the data, question the result of the decision, request reevaluation of the decision, and be informed of the reasoning for the result. Consumers may now also obtain a list of the third parties to whom a controller has sold the consumer’s data, similar to the rights under Oregon’s and Minnesota’s consumer privacy laws.

    Definitions

    Publicly available information now includes information that has been disseminated to the general public from widely distributed media – somewhat broadening the scope of an exception that used to only be applicable to government records and information that a consumer made available to the general public directly.

    Sensitive data has had its definition expanded to include data revealing disability or treatment, status as nonbinary or transgender, information derived from genetic or biometric data, neural data, a variety of financial information (including account number, account log-in information, and credit card numbers), and government identification numbers. Information collected from a child is now sensitive if the controller willfully disregards that the individual is a child; the previous version of the law required actual knowledge.

    Broader Permitted Uses for Secondary Processing

    In order to determine whether consent is required for a secondary processing purpose, the controller must now take into account the following:

    • The reasonable expectations of the consumer;
    • The similarity between the new processing purpose and the old one;
    • The impact the processing may have on the consumer;
    • The relationship between the consumer and the controller and the context in which the data was collected; and
    • The existence of additional safeguards for the data.

    Changes to the Sale of Data

    Controllers may no longer sell sensitive personal data without consent. The amended law raises the age for which sale of personal data is prohibited from 16 to 18 and removes the consent exception sales of data of minors between the age of 13 and 16.

    New Disclosures

    The amended CTDPA calls for additional disclosures in controllers’ privacy notices, including:

    • The categories of third parties to whom data is sold;
    • Whether the controller conducts any processing of personal data for targeted advertising;
    • Whether the controller sells personal data to a third party for targeted advertising;
    • If the controller processes personal data for the purpose of training large language models; and
    • When the privacy notice was last updated.

    Additionally, consumers must be given the opportunity to withdraw their consent following a material retroactive change to the privacy notice.

    Impact Assessments

    Controllers that engage in profiling for the purposes of making a decision that produces a significant effect concerning a consumer will need to conduct impact assessments. Impact assessments must include:

    • A statement by the controller disclosing the purposes and intended uses and benefits afforded by the profiling;
    • An analysis of whether such profiling poses any reasonable or foreseeable heightened risk to the consumer, and, if so:
      • The nature of the heightened risk; and
      • The steps taken to mitigate the heightened risk;
    • A description of the main categories of personal data processed as inputs for the purposes of such profiling and the profiling’s outputs;
    • An overview of the main categories of personal data the controller used to customize such profiling if the controller used data to customize such profiling;
    • Any metrics used to evaluate the performance and known limitations of such profiling;
    • A description of transparency measures; and
    • Monitoring and safeguards employed for the profiling.

    The definition for a decision that produces a significant effect remains largely the same but has been expanded to note explicitly that it includes decisions made on behalf of the controller in addition to decisions made by the controller. Note that these impact assessments are distinct from the data protection assessments associated with processing that presents a heightened risk of harm.

    Key Takeaways

    • The CTDPA will apply to a significantly larger swath of entities with a much lower applicability threshold.
    • Profiling is increasingly becoming a high-compliance burden activity, with numerous rights given to consumers related to it.
    • Impact assessments add another hurdle for entities trying to automate internal processes related to decision making and artificial intelligence.

    Our cross-practice team continues to closely monitor global privacy and cybersecurity developments. To learn more, reach out to one of the authors or your regular McDermott lawyer to discuss the potential legal implications for your business.

    Authors

    Jonathan Ende

    Partner

    Washington, DC

    David P. Saunders

    Partner

    Chicago

    James S. Mann

    Associate

    Los Angeles

    More insights

  • GLP-1 Update: Court Backs FDA in Tirzepatide Compounding Case

    GLP-1 Update: Court Backs FDA in Tirzepatide Compounding Case

    ARTICLE / CLIENT ALERT

    GLP-1 Update: Court Backs FDA in Tirzepatide Compounding Case

    June 13, 2025

    Read time: 4 min

    Key takeaways
    Overview

    On May 7, 2025, the US District Court for the Northern District of Texas upheld the US Food and Drug Administration’s (FDA’s) decision to remove two tirzepatide injection medications from the FDA’s drug shortage list. This ruling will limit most compounding pharmacies, outsourcing facilities, and healthcare providers from using the FDA’s shortage list exception to compound “essentially copies” versions of tirzepatide injection products, likely impacting entity operations.

    In this latest Outsourcing Facilities Association v. FDA decision, the court concluded that the FDA acted within its statutory authority in determining that tirzepatide was no longer in shortage. The court emphasized the agency’s discretion in managing the drug shortage list and found that the plaintiffs had not demonstrated sufficient harm to warrant judicial intervention. This decision effectively affirms the FDA’s position and clears the way for increased enforcement against noncompliant compounding practices.

    In depth

    The FDA has considered the tirzepatide injection shortage resolved since October 2024 despite ongoing objections from industry stakeholders. These include an unsuccessful attempt in March 2025 to obtain a preliminary injunction to stay FDA’s tirzepatide shortage determination.

    Since the FDA considers tirzepatide “available,” stakeholders can no longer rely on the FDA’s shortage list exception to compound “essentially copies” of tirzepatide injections. Instead, compounding pharmacies, outsourcing facilities, and healthcare providers must ensure that tirzepatide products are not substantially the same as, or not administered by the same route as, commercially available products. Other GLP-1 medications, such as semaglutide, have similarly been removed from the drug shortage data, suggesting the national shortage of certain GLP-1 medications appears to be coming to an end. Please see our previous On the Subject for a discussion of the semaglutide supply.

    The May 7, 2025, decision came shortly after the end of the FDA’s discretionary periods for 503A and 503B compounders that are adjusting to the new post-tirzepatide-shortage compounding requirements. We discuss in detail the general requirements for 503A and 503B compounding entities in a previous On the Subject.

    During the tirzepatide discretionary periods, which ended on February 18, 2025, for 503A compounding pharmacies and March 19, 2025, for 503 outsourcing facilities, the FDA announced that it did not intend to take action against compounders for violations of the Food, Drug, and Cosmetic Act based on tirzepatide injection products’ prior inclusion on the FDA’s drug shortage list.

    Because the district court upheld the denial of the preliminary injunction on May 7, compounding pharmacies, outsourcing facilities, and other providers generally cannot rely on the shortage exception to compound “essentially copies” of tirzepatide – and they are not afforded the general protection from FDA enforcement that was available during the discretionary periods.

    As a result, compounding entities should reevaluate their production and operational practices to comply with FDA compounding requirements. The resolution of shortages for tirzepatide and other GLP-1 medications, such as semaglutide, signals a potential shift toward increased FDA enforcement as the agency works to align industry practices with current regulatory standards.

    We will continue to monitor changes in the GLP-1 medication shortage and assess impacts on the industry. For more information, please contact any of the authors of this article or any other member of McDermott’s Food, Drug & Medical Device Regulatory Group.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Paul S. Gadiock

    Partner

    San Francisco

    Marshall E. Jackson , Jr.

    Partner

    Washington, DC

    Lisa Mazur

    Partner

    Chicago

    Jeff Weinstein

    Counsel

    Washington, DC

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    Jae Hyun Lee

    Associate

    New York – One Vanderbilt Avenue

    Tyler Barton

    Associate

    New York – One Vanderbilt Avenue

    Henry Fisher

    Associate

    Washington, DC

    More insights

  • Potential Refund Opportunity for Interest and Penalty Amounts Accrued During COVID-19 Federally Declared Disaster

    Potential Refund Opportunity for Interest and Penalty Amounts Accrued During COVID-19 Federally Declared Disaster

    ARTICLE

    Potential Refund Opportunity for Interest and Penalty Amounts Accrued During COVID-19 Federally Declared Disaster

    Jun 12, 2025

    Read time: 2 min

    Taxpayers who made payments to the Internal Revenue Service (IRS) that included underpayment interest and/or failure-to-file/pay penalties that accrued during all or part of the period between January 20, 2020, through July 10, 2023, should consider filing a refund claim with the IRS to potentially recover accrued interest and penalty amounts.

    Internal Revenue Code (IRC) § 7508A (as in effect during the COVID-19 pandemic), legislative history, regulations, and the US Tax Court’s opinion in Abdo v. Commissioner, 168 T.C. 148 (2024), provide the basis for potential refund claims. IRC § 7508A(d) provides for a mandatory postponement period of certain tax-related obligations, including the suspension of the accrual of underpayment interest for the duration of the COVID-19 incident period plus 60 days (January 20, 2020 – July 10, 2023). IRC § 7508A also appears to have paused the increase of failure-to-file/pay penalties, which are based on the time during which the taxpayer is not in compliance.

    Taxpayers considering this refund opportunity should be aware that the statute of limitations to file a refund claim expires three years from the filing deadline of the original tax return or two years from the date on which payment was made – whichever is later (unless the statute of limitations period was otherwise extended). This refund opportunity may apply to underpayment interest and/or penalties paid with respect to federal income, estate, gift, employment, or excise taxes.

    In depth
    Authors

    Shawn O'Brien

    Partner

    Houston

    Samuel F. Hamer

    Associate

    Washington, DC

    More insights
    Endnotes

  • Oregon Enacts Expansive Corporate Practice of Medicine Bill

    Oregon Enacts Expansive Corporate Practice of Medicine Bill

    ARTICLE / CLIENT ALERT

    Oregon Enacts Expansive Corporate Practice of Medicine Bill

    June 12, 2025

    Read time: 4 min

    Key takeaways
    Overview

    On June 9, 2025, the Oregon legislature enacted Senate Bill (SB) 951, which prohibits certain ownership of and actions related to professional medical entities and aims to modernize Oregon’s corporate practice of medicine (CPOM) doctrine. The salient CPOM prohibitions included in SB 951 will become effective on January 1, 2026, for all management services organization-professional corporation (MSO-PC) structures created after June 9, 2025, with a three-year grace period ending on January 1, 2029, for currently existing MSO-PCs.

    In depth

    As we reported in a previous On the Subject, SB 951 prohibits professional medical entities from relinquishing control over their “assets, business operations, clinical practices or decisions or the clinical practices or decisions of a physician.” This prohibition does not include:

    • Selling, leasing, or assigning the right to possess corporate assets, inclusive of any leased or owned property, to an MSO
    • Supporting, advising, and consulting on all matters of the professional medical entity’s business operations, including accounting and budgeting, personnel, real estate and facilities management, and compliance support, for the benefit of the professional medical entity
    • Advising and providing direction to the professional medical entity related to its participation in value-based contracts, payer arrangements, or vendor contracting.

    Shareholders, directors, and officers of an MSO are prohibited from owning or controlling a majority of shares of; serving as a director, officer, employee, or independent contractor of; or receiving compensation from the MSO for participating in the management of a professional medical entity under contract with the MSO. SB 951 provides an exception for physicians and independent providers below a 10% ownership threshold, whereby such individuals may serve as independent contractors of the MSO, provided that they are reimbursed at market rates for their services. A limited carve out for practices solely providing telemedicine services allows for dual employment of physicians by both the MSO and the PC.

    SB 951 also prohibits various restrictive covenant clauses and agreements. Noncompetition agreements, except as applicable to providers with greater than 10% ownership stakes in the professional medical entities, are rendered unenforceable. Nondisclosure and nondisparagement agreements are also rendered void and unenforceable unless they are related to trade secrets and good-faith reports or are contained within termination agreements with whistleblower protections. SB 951 also restricts the use of stock transfer restriction agreements commonly found in MSO-PC structures, except under limited circumstances related to civil and criminal actions against a shareholder or member or the termination of the management agreement by the professional medical entity.

    The Oregon legislature is currently considering House Bill 3410, which would amend SB 951 to broaden dual employment exceptions and allowable triggering events under securities transfer restriction agreements. This amendment, if passed, would allow greater structural flexibility for MSO-PC structures but would not amend the central prohibitions on MSOs interfering in the clinical operations of professional medical entities.

    For more information or for assistance with SB 951, please contact one of the authors of this article or your regular McDermott lawyer.

    Authors

    Patrick Zanayed

    Partner

    Chicago

    Larry C. Guess

    Partner

    Chicago

    Jae Hyun Lee

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • DOJ Revives FCPA Enforcement With Narrower Scope

    DOJ Revives FCPA Enforcement With Narrower Scope

    ARTICLE / CLIENT ALERT

    DOJ Revives FCPA Enforcement With Narrower Scope

    June 12, 2025

    Read time: 5 min

    Key takeaways
    Overview

    On February 10, 2025, President Donald Trump issued an executive order pausing new Foreign Corrupt Practices Act (FCPA) investigations for 180 days (the EO). The EO directs the US Department of Justice (DOJ) to review existing matters, guidelines, and policies governing FCPA enforcement and investigations, and to issue updated guidance that advances US national security and economic interests.

    In response, on June 9, 2025, US Deputy Attorney General Todd Blanche issued “Guidelines for Investigations and Enforcement of the FCPA” (the Guidelines). In remarks the following day, the Head of DOJ’s Criminal Division, Matthew R. Galeotti, announced that the Criminal Division would resume enforcement of the FCPA “firmly but fairly.”

    While bribery is briefly identified as a focus area in the DOJ’s May 2025 White Collar Enforcement Plan, the Guidelines represent the first substantive FCPA-specific guidance issued by the DOJ following the EO. They give insight into the types of investigations and enforcement actions we expect to see going forward – and, most importantly, they indicate that the DOJ will continue to hold companies and individuals accountable for foreign corruption.

    In depth

    Four Factors

    The Guidelines direct prosecutors to apply four non-exhaustive factors when determining whether to pursue FCPA investigations or enforcement actions.

    • Connection to Cartels and Transnational Criminal Organizations (TCOs): The DOJ will prioritize matters with a demonstrable nexus to cartel or TCO operations, consistent with a January 2025 EO designating such organizations as foreign terrorist threats. Prosecutors should consider whether the alleged conduct:
      • Is associated with the criminal operations of a cartel or TCO;
      • Involves shell companies or money launderers linked to cartels or TCOs; or
      • Involves foreign officials who have received bribes from cartels or TCOs.
    • Harm to US Business Interests: The DOJ will focus on foreign bribery that harms the competitiveness of US businesses. The Guidelines specify that enforcement will not turn on where a company is headquartered, but whether the conduct:
      • Deprived specific and identifiable US entities of a fair opportunity to compete; and/or
      • Caused economic harm to specific US companies or individuals.

    Prosecutors are also directed to assess whether foreign officials’ demands harmed identifiable US entities in Foreign Extortion Prevention Act (FEPA) cases, which address the demand side of bribery.

    • Focus on Defense, Intelligence, and Critical Infrastructure Sectors: The DOJ will prioritize cases involving the bribery of foreign officials where the misconduct could harm US national security interests. The Guidelines state that FCPA enforcement will focus on sectors such as defense, intelligence, critical minerals, and strategic infrastructure.
    • Serious and Egregious Misconduct: The DOJ will deprioritize enforcement of “de minimis or low-dollar generally accepted business courtesies,” and focus on high-impact corruption involving:
      • “Substantial” bribe payments;
      • Sophisticated concealment of bribes;
      • Fraudulent conduct used to facilitate the scheme; and
      • Obstruction of justice.

    Additional Considerations

    The Guidelines emphasize that these four factors are not exhaustive and that prosecutors must also consider broader DOJ policies and case-specific circumstances, including:

    • Justice Manual Standards: The Principles of Federal Prosecution remain applicable and require evaluation of the nature and seriousness of the offense, deterrent value, and overall interests of justice.
    • Procedural Posture of the Case: Ongoing matters – such as those involving filed indictments or executed corporate resolutions – may be treated differently from investigations in their preliminary stages.
    • Potential Role of Foreign Law Enforcement: To prioritize cases for US involvement, prosecutors are instructed to consider whether a foreign law enforcement authority is willing and able to investigate the same misconduct.

    Conclusion

    The new Guidelines represent a marked shift toward a more targeted and strategic approach to FCPA enforcement. While the overall volume of enforcement activity may decline, companies operating in high-risk sectors or jurisdictions – particularly those with exposure to cartels, national security interests, or direct competition with US businesses – should remain vigilant. Compliance programs should continue to prioritize high-impact risk areas and be prepared for heightened scrutiny in cases involving serious or systemic misconduct.

    At the same time, multinational companies should note that enforcement risk may shift rather than disappear. In March 2025, regulators from the United Kingdom, France, and Switzerland launched the International Anti-Corruption Prosecutorial Taskforce, a multilateral initiative to coordinate cross-border investigations and prosecutions of foreign bribery. This taskforce may fill gaps left by reduced US enforcement, particularly in matters involving European operations or foreign officials. As US priorities narrow, companies should anticipate continued – and in some cases increased – scrutiny from non-US enforcement authorities.

    Authors
    More insights

  • CMS Requires Hospitals to Publish More Pricing Information, Signals Focus on Enforcement

    CMS Requires Hospitals to Publish More Pricing Information, Signals Focus on Enforcement

    ARTICLE / CLIENT ALERT

    CMS Requires Hospitals to Publish More Pricing Information, Signals Focus on Enforcement

    June 9, 2025

    Read time: 5 min

    Key takeaways
    Overview

    On May 22, 2025, the Centers for Medicare & Medicaid Services (CMS) released new guidance for compliance with the hospital price transparency rule and published a request for information (RFI) seeking ways to bolster hospital compliance with the rule. The guidance and RFI suggest that the second Trump administration remains focused on ensuring that hospitals comprehensively and accurately disclose their prices.

    In depth

    Background

    The rule was first promulgated under the prior Trump administration and remained in place with modifications throughout the Biden administration. It requires hospitals to publicly disclose their “standard charges” in a “machine readable file” (MRF). Negotiated rates with third-party payers are considered one type of “standard charge.”

    Effective July 1, 2024, the Biden administration supplemented the Trump regulation to require hospitals to disclose an “estimated allowed amount” in cases where the hospital had negotiated a third-party payer rate based on a percentage or algorithm. The estimated allowed amount was defined as the average dollar amount that the hospital had historically received from the third-party payer. CMS recommended that hospitals encode nine 9s (999999999) in cases where there were insufficient historic claims to derive an estimated allowed amount.

    The Executive Order

    On May 22, 2025, President Trump issued Executive Order 14221, “Making America Healthy Again by Empowering Patients with Clear, Accurate and Actionable Healthcare Pricing Information.” The executive order directed the US Department of Health and Human Services to issue guidance ensuring that pricing information is standardized and easily comparable across hospitals and to update enforcement policies to ensure hospital compliance.

    The Guidance

    CMS issued the guidance concurrently with the executive order. The guidance observed that hospitals were encoding nine 9s much more frequently than expected. CMS found that more than 90% of estimated allowed amounts listed by a sample of hospitals encoded nine 9s. The guidance instructed that nine 9s were no longer acceptable for items or services. It also stated that hospitals must calculate the estimated allowed amount based on the average charge over the prior 12-month period as long as there was at least one charge during that period. If an item or service was not charged during the period, the hospital must encode a value of its expectation of what the charge would be for that item or service. The guidance directs hospitals to note that there were zero instances of the item or service in the 12 months prior to posting the file.

    The Request for Information

    CMS also issued an RFI concurrently with the executive order and guidance. The RFI noted that CMS had received comments from the public and stakeholders regarding its assessment of the accuracy and completeness of the charge information displayed by hospitals. The RFI solicited public comments responding to the following questions to inform CMS program planning and decision making:

    • Should CMS specifically define the terms “accuracy of data” and “completeness of data” in the context of hospital price transparency requirements, and, if yes, then how?
    • What are your concerns about the accuracy and completeness of the hospital price transparency MRF data? Please be as specific as possible.
    • Do concerns about accuracy and completeness of the MRF data affect your ability to use hospital pricing information effectively? For example, are there additional data elements that could be added, or others modified, to improve your ability to use the data? Please provide examples.
    • Are there external sources of information that may be leveraged to evaluate the accuracy and completeness of the data in the MRF? If so, please identify those sources and how they can be used.
    • What specific suggestions do you have for improving the hospital price transparency compliance and enforcement processes to ensure that the hospital pricing data is accurate, complete, and meaningful? For example, are there any changes that CMS should consider making to the CMS validator tool, which is available to hospitals to help ensure they are complying with hospital price transparency requirements, so as to improve accuracy and completeness?
    • Do you have any other suggestions for CMS to help improve the overall quality of the hospital price transparency data?

    Comments are due by 11:59 pm EDT on July 21, 2025.

    Analysis

    The guidance and RFI signal a continued commitment from the Trump administration to enforcing hospital price transparency requirements. The updated guidance emphasizes standardization and data quality in hospital pricing disclosures – two areas likely to be focal points for future compliance monitoring and enforcement. Enforcement penalties can be significant: CMS may impose civil monetary penalties of up to $5,500 per day for noncompliance. CMS publicly lists hospitals that are noncompliant and have received penalty notices, adding reputational pressure to financial consequences. Please see our previous On the Subject for an in-depth discussion of enforcement penalties. Responding to audits and adverse audit findings may prove technical- and resource-heavy for affected hospitals.

    Hospitals may find that listing estimated allowed amounts will require significant resources above and beyond the material investments made to date, including new data analytics capabilities and internal process adjustments. Calculating estimated allowed amounts in all cases may prove challenging for institutions with complex service offerings or legacy data systems.

    CMS seeks input on how to define key terms, validate data, and structure enforcement. Stakeholders should consider submitting comments by the July 21, 2025, deadline to inform CMS of the potential implications of more expansive or exacting disclosure requirements.

    Authors

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Steven J. Schnelle

    Partner

    New York – One Vanderbilt Avenue

    Tyler Barton

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • The Fix Is In: FTC and DOJ Permit Structural Remedies for Two Major Tech Mergers

    The Fix Is In: FTC and DOJ Permit Structural Remedies for Two Major Tech Mergers

    ARTICLE / CLIENT ALERT

    The Fix Is In: FTC and DOJ Permit Structural Remedies for Two Major Tech Mergers

    June 9, 2025

    Read time: 5 min

    Key takeaways
    Overview

    The Federal Trade Commission (FTC) and the US Department of Justice (DOJ) each recently announced that they would accept structural remedies to address concerns that two transactions in the technology industry would reduce competition. These two divestitures are the first consent decrees under the Trump administration and demonstrate the current administration’s willingness to use structural remedies to clear transactions – a marked change from the FTC’s and DOJ’s position during the Biden administration.

    On May 28, 2025, the FTC mandated that Synopsys, Inc. and Ansys, Inc. divest assets to mitigate antitrust issues arising from their merger. Synopsys, a chip design software developer, and Ansys, a simulation software developer, announced the $35 billion acquisition in January 2024. Under the proposed consent order, the FTC is requiring Synopsys to divest optical software tools and photonic software tools and Ansys to divest PowerArtist, a power consumption analysis tool.

    The DOJ is also requiring divestitures to mitigate competition concerns regarding a transaction between Keysight Technologies and Spirent Communications. On June 2, 2025, the DOJ announced it will require Spirent to divest its high-speed ethernet testing, network security testing, and radio frequency channel emulation tools to allow the transaction to proceed.

    In depth

    Why It Matters

    FTC Chairman Andrew Ferguson and DOJ Assistant Attorney General (AAG) Abigail Slater are upholding their prior policy statements to facilitate dealmaking via structural merger remedies rather than blocking transactions outright. This represents a significant change from the antitrust agencies’ unwillingness to consider remedies during the Biden administration. Although the antitrust agencies are now open to settling merger cases, agency officials emphasized that behavioral remedies remain disfavored and structural remedies will only be accepted if they involve the sale of a standalone business.

    Chairman Ferguson issued a statement along with the proposed consent order in the Synopsys-Ansys merger, affirming the FTC’s willingness to consider structural remedies when “it involves the sale of a standalone or discrete business, or something very close to it, along with all tangible and intangible assets necessary (1) to make that line of business viable, (2) to give the divestiture buyer the incentive and ability to compete vigorously against the merged firm, and (3) to eliminate to the extent possible any ongoing entanglements between the divested business and the merged firm.” Chairman Ferguson noted that all three of these factors were present in the fix   the FTC accepted in the Synopsys-Ansys merger. He also indicated that settlement can be a powerful tool to ensure innovation is not stunted while protecting consumers from reduced competition.

    Similarly, AAG Slater issued a press release along with the DOJ consent decree in the Keysight-Spirent deal, stating that “this structural solution preserves competition for key testing equipment used to ensure that data moves quickly and securely across the world.” She also noted that like the FTC, the DOJ is concerned with protecting consumers and ensuring innovation, and that settlement is a means to prevent chilling dealmaking.

    Settlement may aid in the dealmaking process, but even after final judgment approving a structural remedy, there may be lingering uncertainty for the merging parties. The DOJ consent decree in the Keysight-Spirent transaction contains a provision that permits the DOJ – in its sole discretion – to reopen the proceeding any time during the five-year period following the entry of the final judgment if it believes the final judgment has not fully redressed the alleged anticompetitive harm. The DOJ may seek additional relief, including divestiture of additional assets. Thus, although the DOJ is seeking to promote mergers and acquisitions (M&A) through the use of tailored remedies, merging parties should be aware that even if they negotiate a settlement to resolve the agency’s concerns, if the consent decree contains a provision allowing the DOJ to reopen its proceeding, the potential for the DOJ to seek further remedies remains – even after the entry of final judgment.

    The consent decree in the FTC Synopsys-Ansys transaction highlights another trend: international coordination in merger enforcement. Prior to negotiating remedies with the FTC and the DOJ, Synopsys and Ansys had negotiated settlements with foreign competition authorities in Europe, the United Kingdom, South Korea, and Japan. Notably, the proposed divestitures announced by the FTC mirror the settlements negotiated with these other jurisdictions.

    Conclusion

    The FTC’s and DOJ’s recent decisions to accept structural remedies to clear merger investigations represents a positive change for companies looking to engage in M&A. Although leaders at both agencies signaled they are willing to consider strong divestiture packages from merging parties, it remains to be seen whether the Trump administration FTC or DOJ will accept behavioral remedies.

    If you have questions about what this divestiture order could mean for your business, reach out to your regular McDermott lawyer or the authors of this article.

    Shannon McCracken, a summer associate in the Washington, DC, office, also contributed to this article.

    Authors

    Lisa P. Rumin

    Partner

    Washington, DC

    Joel R. Grosberg

    Partner

    Washington, DC

    More insights

  • SCOTUS Clarifies Standard for Evaluating “Reverse” Discrimination Cases

    SCOTUS Clarifies Standard for Evaluating “Reverse” Discrimination Cases

    ARTICLE / CLIENT ALERT

    SCOTUS Clarifies Standard for Evaluating “Reverse” Discrimination Cases

    June 9, 2025

    Read time: 3 min

    Key takeaways
    Overview

    On June 5, 2025, the Supreme Court of the United States resolved the split among federal circuits and held that the same standard used to evaluate claims under Title VII of the Civil Rights Act of 1964 applies to all plaintiffs, regardless of whether the plaintiff is a member of a minority or majority group.

    In Ames v. Ohio Dept. of Youth Services, which was an appeal from the US Court of Appeals for the Sixth Circuit, the Supreme Court analyzed the standard in “reverse” discrimination cases under Title VII. “Reverse” discrimination refers to discrimination experienced by a member of a majority group by or in favor of a member of a group that historically faced discrimination. In Ames, appellant Marlean Ames (who identifies as heterosexual) worked for the Ohio Department of Youth Services (the Department) for 15 years when she interviewed for a new management position. The Department selected a lesbian candidate for the position instead of Ames, demoted Ames from her position, and replaced her with a gay male employee. Ames sued the Department, alleging that she was denied the promotion and ultimately demoted in violation of Title VII because of her heterosexual orientation.

    Vacating the Sixth Circuit’s ruling, the Supreme Court struck down the requirement that plaintiffs of a majority group must satisfy a heightened evidentiary standard to prevail on a Title VII claim. The “background circumstances” rule required Title VII plaintiffs who are members of majority groups to show that the circumstances of the adverse action establish that the employer discriminates against the majority. This standard added a heightened evidentiary requirement for majority plaintiffs to establish a prima facie case under the McDonnell Douglas framework for assessing Title VII claims. In Ames, the Supreme Court unanimously ruled that the background circumstances standard violated Title VII and Supreme Court precedent.

    As the Ames decision has clarified the standard to be used in all Title VII cases, employers should ensure that each adverse employment action is made based on consistently applied practices and policies, without regard to any personal characteristics covered by Title VII and state and local antidiscrimination laws. Any practices that give preference to historically disadvantaged groups must be scrutinized and assessed for the risk of potential “reverse” discrimination claims. Employers should also evaluate all employee complaints equally and refrain from giving special consideration to complaints made by workers in what have historically been protected classes.

    In depth
    Authors

    Tony W. Torain II

    Partner

    Washington, DC, New York – One Vanderbilt Avenue

    More insights